uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
167 articles with uniQure
-
uniQure Announces Clinical Data Presentations At The Upcoming International Society On Thrombosis And Hemostasis (ISTH) Congress
6/23/2017
-
uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile And Broad Utilization Of AAV5-Based Gene Therapies
6/15/2017
-
uniQure Presents New Data Demonstrating Successful And Effective Transduction Of AAV5 Vector In The Presence Of Pre-Existing Neutralizing Antibodies In Non-Human Primates
5/10/2017
-
uniQure Announces First Quarter 2017 Financial Results And Highlights Recent Company Progress
5/9/2017
-
uniQure Presents New Preclinical Data On AMT-130 In Huntington’s Disease At CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference
4/26/2017
-
uniQure Receives EMA Priority Medicines (PRIME) Designation For AMT-060 In Hemophilia B
4/25/2017
-
uniQure Announces It Will Not Seek Marketing Authorization Renewal For Glybera In Europe
4/20/2017
-
uniQure Publishes Data Demonstrating Wide Distribution Of AAV5 In The Central Nervous System
4/4/2017
-
uniQure Announces Presentations At Upcoming April Conferences
4/3/2017
-
uniQure Announces 2016 Financial Results And Provides Update On Company Progress
3/15/2017
-
uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
3/3/2017
-
uniQure Announces Presentations At Upcoming March Conferences
3/1/2017
-
uniQure Announces Presentations At Upcoming February Conferences
2/6/2017
-
uniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
1/30/2017
-
uniQure Release: Company Appoints Alexander Kuta As Senior Vice President Of Regulatory Affairs
1/25/2017
-
uniQure Appoints Matthew Kapusta As Chief Executive Officer
12/19/2016
-
uniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
12/5/2016
-
uniQure To Present At The Genetic Rx Boston Biotech Conference At Harvard Medical School
12/2/2016
-
uniQure Announces Financial Results For Third Quarter 2016 And Provides Update On Company Progress
11/22/2016
-
uniQure Shakes Up R&D to Refocus Pipeline, to Eliminate 20-25% of Workforce By End of 2017
11/15/2016